References
- Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427–448.
- Monath TP, Gershman M, Staples JE, et al. Yellow fever vaccine. In: Plotkin SA, Orenstein W, Offit PA, editors. Vaccines. Philadelphia: Elsevier-Saunders; 2013. p. 870–968.
- Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–5775.
- Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–173.
- De Menezes Martins R, Da Luz Fernandes Leal M, Homma A. Safety of yellow fever vaccine. Hum Vaccin Immunother. 2015;11(9);2183–2187.
- Beck AS, Barrett AD. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14(11):1479–1492.
- Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3(5):e75.
- Miller BR, Mitchell CJ, Ballinger ME. Replication, tissue tropisms and transmission of yellow fever virus in Aedes albopictus. Trans R Soc Trop Med Hyg. 1989;83(2):252–255.
- Engelmann F, Josset L, Girke T, et al. Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl Trop Dis. 2014;8(11):e3295.
- Feral rhesus macaque. Available from: https://en.wikipedia.org/wiki/Feral_rhesus_macaque.
- Case of yellow fever in monkeys is confirmed in Tocantins. Available from: http://www.promedmail.org/direct.php?id=3551886.
- The early history of yellow fever. Available from: http://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1004&context=yellow_fever_symposium.
- Crosby MC. The American plague. Berkley (NY): Berkley Books; 2007.
- Yellow fever the plague of Memphis. Available from: http://historic-memphis.com/memphis-historic/yellow-fever/yellow-fever.html.
- Yellow fever and the Reed commission. Available from: http://exhibits.hsl.virginia.edu/yellowfever/mosquitoes/.
- Monath TP, Craven RB, Adjukiewicz A, et al. Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980;29(5):912–928.
- Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91–97.
- Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358(9276):98–104.
- Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358(9276):121–122.
- Seligman SJ, Cohen JE, Itan Y, et al. Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data. Am J Trop Med Hyg. 2014;90(2):267–271.
- Monath TP. Dengue and yellow fever–challenges for the development and use of vaccines. N Engl J Med. 2007;357(22):2222–2225.
- Casanova JL. Severe infectious diseases of childhood as monogenic inborn errors of immunity. Proc Natl Acad Sci U S A. 2015;112(51):E7128–7137.
- Casanova JL. Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci U S A. 2015;112(51):E7118–7127.
- Moreno ES, Spinola R, Tengan CH, et al. Yellow fever epizootics in non-human primates, Sao Paulo state, Brazil, 2008–2009. Rev Inst Med Trop Sao Paulo. 2013;55(1):45–50.
- Markoff L. Yellow fever outbreak in Sudan. N Engl J Med. 2013;368(8):689–691.
- CDC - Yellow Fever. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/yellow-fever.
- Seligman SJ. Yellow fever - africa (25): Angola comment [Internet]. 2016. [cited 2016 Mar 19]. Available from: http://www.promedmail.org/
- Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–1368.
- de Menezes Martins R, Maia DLDS, dos Santos EM, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol. 2010;2:178–183.
- Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256–3263.
- Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077–6082.
- Collaborative group for studies of yellow fever V. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110(6):771–780.
- Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12(2):491–502.
- Staples JE, Bocchini JA Jr, Rubin L, et al. Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–650.
- Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90–100.
- Mayo Clinic - Myasthenia gravis. Available from: http://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/basics/causes/con-20027124.
- Genetics home reference - Myasthenia gravis. Available from: https://ghr.nlm.nih.gov/condition/myasthenia-gravis.
- Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149.
- Dry season. Available from: https://en.wikipedia.org/wiki/Dry_season.
- Weather. Available from: https://weather.com/weather.
- Biscayart C, Carrega ME, Sagradini S, et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine. 2014;32(11):1266–1272.
- Yellow fever reported cases. Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tsincidenceyfever.html.
- Anon. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA. 1966;198(6):671–672.
- Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine. 2007;25(50):8480–8485.
- Casanova JL, Conley ME, Seligman SJ, et al. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–2149.
- Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31(14):1819–1829.
- Dunn G, Klapsa D, Wilton T, et al. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog. 2015;11(8):e1005114.
- Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85(1):131–134.
- Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364(14):1326–1333.
- Pereira RC, Silva AN, Souza MC, et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine. 2015;33(35):4261–4268.
- Maciel M Jr, Cruz Fda S, Cordeiro MT, et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis. 2015;9(4):e0003693.
- Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis. 2014;14:391.